Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea
Palatin to Receive $500,000 Upfront Entitled to Receive $3.0 Million on First Commercial Sale in Korea and Up to $37.5 Million in Sales Related Milestones plus Royalties on Net Sales Nov 21, 2017, 06:30 ET CRANBURY, N.J., Nov. 21, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into …